Literature DB >> 2891625

Mother-to-child transmission of human T-cell leukemia virus type I (HTLV-I): a fifteen-year follow-up study in Okinawa, Japan.

K Kusuhara1, S Sonoda, K Takahashi, K Tokugawa, J Fukushige, K Ueda.   

Abstract

Okinawa prefecture is one of the endemic areas for adult T-cell leukemia/lymphoma (ATLL) in Japan. In this study, 2,013 serum specimens drawn serially over a period of 15 years (1968-1983) from 311 mother/child pairs in Okinawa were tested for antibodies to human T-cell leukemia virus type I (HTLV-I) by enzyme-linked immunosorbent assay and by indirect immunofluorescence. The prevalence rate of HTLV-I antibodies was 20.9% (65 cases) in the mothers and 3.2% (10 cases) in the children. Of the 65 seropositive mothers, 10 (15.4%) had seropositive children. This study revealed a significant difference between the prevalence rates of HTLV-I antibodies in mothers and children. In addition, children born to seropositive mothers had acquired their HTLV-I antibodies by the age of 3 years, and were still seropositive at the age of 18 years. No initially seronegative child was found to have seroconverted during the period investigated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891625     DOI: 10.1002/ijc.2910400607

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Improvement of simultaneous detection of antibodies to Gag and envelope antigens of human T-lymphotropic virus type I by western immunoblot assay.

Authors:  H Miyakoshi; M Sugimoto; H Igarashi; H Honda; R Fujino; M Mizukoshi
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis.

Authors:  J K Cruickshank; J H Richardson; O S Morgan; J Porter; P Klenerman; J Knight; A L Newell; P Rudge; A G Dalgleish
Journal:  BMJ       Date:  1990-02-03

Review 4.  Malignant lymphomas in Japan: epidemiological analysis of adult T-cell leukemia/lymphoma (ATL).

Authors:  K Tajima
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

5.  Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response.

Authors:  Atsuhiko Hasegawa; Takashi Ohashi; Shino Hanabuchi; Hirotomo Kato; Fumiyo Takemura; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 6.  Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.

Authors:  Mari Kannagi
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 7.  Cancer burden and trends in the Asian Pacific Rim region.

Authors:  Binh H Yang; D Maxwell Parkin; Lin Cai; Zuo Feng Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2004 Apr-Jun

8.  Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.

Authors:  Y Tanaka; R Tanaka; E Terada; Y Koyanagi; N Miyano-Kurosaki; N Yamamoto; E Baba; M Nakamura; H Shida
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

9.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children.

Authors:  S Hino; S Katamine; T Miyamoto; H Doi; Y Tsuji; T Yamabe; J E Kaplan; D L Rudolph; R B Lal
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.